Share This Page
Hydrochlorothiazide; methyldopa - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for hydrochlorothiazide; methyldopa and what is the scope of freedom to operate?
Hydrochlorothiazide; methyldopa
is the generic ingredient in five branded drugs marketed by Merck, Chartwell Rx, Dava Pharms Inc, Ivax Sub Teva Pharms, Parke Davis, Purepac Pharm, Rising, Sandoz, Strides Pharma Intl, Teva, and Watson Labs, and is included in forty-one NDAs. Additional information is available in the individual branded drug profile pages.Summary for hydrochlorothiazide; methyldopa
| US Patents: | 0 |
| Tradenames: | 5 |
| Applicants: | 11 |
| NDAs: | 41 |
| Raw Ingredient (Bulk) Api Vendors: | 3 |
| Patent Applications: | 159 |
| DailyMed Link: | hydrochlorothiazide; methyldopa at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for hydrochlorothiazide; methyldopa
US Patents and Regulatory Information for hydrochlorothiazide; methyldopa
Hydrochlorothiazide and Methyldopa Market Dynamics, Patent Status, and Financial Trajectory
Hydrochlorothiazide/methyldopa is a mature, low-value antihypertensive combination with limited current commercial activity. Its historical product, Aldoril, combined the thiazide diuretic hydrochlorothiazide with the centrally acting alpha-2 agonist methyldopa. The combination has no meaningful remaining exclusivity moat, faces extensive substitution from inexpensive single-agent and fixed-dose hypertension products, and has little identifiable standalone revenue exposure. Its residual clinical relevance is concentrated in legacy prescribing and selected pregnancy-related hypertension settings, where methyldopa remains available but is no longer a leading first-line option in many guidelines.
What is the current market status of hydrochlorothiazide and methyldopa?
Hydrochlorothiazide and methyldopa are both established generic active pharmaceutical ingredients. The combination was historically marketed in the United States as Aldoril by Merck, with multiple strengths. Current commercial activity is fragmented and primarily generic.
| Metric | Hydrochlorothiazide/methyldopa assessment |
|---|---|
| Drug class | Thiazide diuretic plus centrally acting alpha-2 agonist |
| Historical U.S. brand | Aldoril |
| Primary indication | Hypertension |
| FDA pathway | Legacy small-molecule NDA and subsequent generic ANDA pathways |
| Current exclusivity | None of commercial significance |
| Orange Book relevance | Historical product listing; no commercially meaningful active exclusivity identified |
| Competitive position | Weak versus modern antihypertensive combinations |
| Revenue profile | Low and fragmented; no material branded revenue base |
| Main demand drivers | Low acquisition cost, legacy prescribing, limited use of methyldopa in pregnancy |
| Main demand constraints | Sedation, depression, hepatotoxicity, hemolytic anemia, frequent dosing, and superior alternatives |
Hydrochlorothiazide remains widely prescribed as a low-cost diuretic, usually as monotherapy or in combinations with lisinopril, losartan, valsartan, telmisartan, amlodipine, or other agents. Methyldopa has a narrower role because of tolerability and safety monitoring requirements. The combination therefore does not benefit from hydrochlorothiazide's broad market volume to the same extent as products paired with ACE inhibitors, angiotensin receptor blockers, or calcium-channel blockers.
How does the hydrochlorothiazide/methyldopa market compare with competing antihypertensive combinations?
The combination is commercially disadvantaged because the two ingredients do not have equivalent current demand.
Hydrochlorothiazide's competitive market
Hydrochlorothiazide is a high-volume generic ingredient. Its market is supported by:
- Low manufacturing cost.
- Broad physician familiarity.
- Use in fixed-dose combinations.
- Longstanding reimbursement acceptance.
- Availability from numerous generic manufacturers.
Its principal competition includes chlorthalidone and indapamide among thiazide-type diuretics, as well as combination products pairing hydrochlorothiazide with renin-angiotensin system inhibitors.
Methyldopa's narrower market
Methyldopa is used less frequently because it can cause:
- Sedation and cognitive effects.
- Depression.
- Orthostatic symptoms.
- Hepatotoxicity.
- Positive Coombs test and hemolytic anemia.
- Hyperprolactinemia.
- Rebound or worsening hypertension after abrupt discontinuation.
The American College of Obstetricians and Gynecologists has identified labetalol, extended-release nifedipine, and methyldopa as medications used for chronic hypertension in pregnancy, while noting that methyldopa may be less effective and have more adverse effects than some alternatives (American College of Obstetricians and Gynecologists, 2019).
| Product category | Current market strength | Relationship to methyldopa/HCTZ |
|---|---|---|
| Hydrochlorothiazide monotherapy | High generic volume | Directly competes with the diuretic component |
| HCTZ/ACE inhibitor combinations | High | More clinically aligned with current hypertension treatment |
| HCTZ/ARB combinations | High | Stronger commercial and prescribing position |
| Chlorthalidone products | Moderate | Alternative thiazide-type therapy |
| Methyldopa monotherapy | Low to moderate, concentrated in selected uses | Directly competes with the central-acting component |
| Labetalol | High in pregnancy hypertension | Major alternative to methyldopa |
| Extended-release nifedipine | High in pregnancy hypertension | Major alternative to methyldopa |
| Amlodipine-based combinations | High | Competes in general hypertension |
| Newer branded cardiovascular products | Variable | Usually not direct substitutes on price, but compete for treatment share |
When did hydrochlorothiazide/methyldopa lose exclusivity?
Commercial exclusivity ended decades ago. Both active ingredients were introduced in the 20th century, and the relevant product patents and regulatory exclusivities expired long before the modern generic market developed.
The U.S. Food and Drug Administration's Orange Book framework is relevant to listed drug patents and regulatory exclusivity, but an old combination such as Aldoril does not retain a current patent-based barrier comparable to newer branded drugs (FDA, 2024a). Any historical Aldoril patents would have expired based on their filing dates and statutory patent terms.
| Exclusivity element | Status |
|---|---|
| New chemical entity exclusivity | Expired |
| Original formulation exclusivity | Expired |
| Historical combination patents | Expired |
| Method-of-use exclusivity | Expired or commercially immaterial |
| Pediatric exclusivity | Not commercially relevant |
| Orphan-drug exclusivity | Not applicable |
| Patent-term extension | No current commercial effect |
| Generic substitution barrier | None of material significance |
What patents protect hydrochlorothiazide and methyldopa products?
No active patent estate appears to provide meaningful protection for the legacy hydrochlorothiazide/methyldopa combination in the United States. The relevant intellectual-property categories are historical composition patents, formulation patents, manufacturing patents, and method-of-use claims.
Composition and combination patents
The active ingredients are long-established generic molecules. Composition-of-matter protection has expired. A combination patent could theoretically have covered the use of methyldopa with hydrochlorothiazide, but any such patent would also be expired given the age of the product.
Formulation patents
A modern formulation patent could cover controlled release, modified dissolution, abuse deterrence, or a specialized dosage form. Those protections do not define the legacy Aldoril market. Standard immediate-release tablets are generally exposed to generic competition.
Manufacturing patents
Manufacturing-process patents could affect a particular supplier's production economics, but they would not prevent other manufacturers from producing the active ingredients through alternative processes. No manufacturing patent is known to create a broad market barrier for the finished combination.
Method-of-use patents
The hypertension indication is old and broad. Any method-of-use protection associated with conventional treatment of hypertension would be expired. A new patent could theoretically protect a narrow patient population or dosing protocol, but that would represent a new development rather than protection of the legacy product.
What is the Orange Book status of hydrochlorothiazide/methyldopa?
The Orange Book is unlikely to provide a meaningful current barrier for generic hydrochlorothiazide/methyldopa. FDA Orange Book listings are tied to approved reference products, patent certifications, and regulatory exclusivity. For an old combination with no active exclusivity, generic applicants generally face an abbreviated approval pathway without a commercially significant patent challenge.
| Orange Book issue | Assessment |
|---|---|
| Reference listed drug | Historical Aldoril product record |
| Active patent protection | No material active protection identified |
| Regulatory exclusivity | Expired |
| Paragraph IV significance | Low |
| 30-month stay risk | Low absent a newly listed patent |
| Generic approval pathway | ANDA-based, subject to reference-product and product-specific requirements |
| Current litigation leverage | Minimal |
A Paragraph IV certification would have limited strategic value where no enforceable patent remains. The main regulatory issues are bioequivalence, product availability, labeling, manufacturing compliance, and the status of the reference product rather than patent validity.
Which companies are challenging hydrochlorothiazide/methyldopa exclusivity?
No material contemporary Paragraph IV campaign or branded-generic patent dispute is associated with the legacy combination. Generic competition has existed for many years, and the market is characterized by routine ANDA competition rather than high-value patent litigation.
Potential suppliers of the separate ingredients and combination tablets may include large generic manufacturers, contract manufacturers, and regional suppliers. Supplier participation can change because of procurement economics, drug shortages, manufacturing decisions, or discontinuation notices. The commercial market should therefore be assessed through current FDA product records and distributor availability rather than historical brand ownership.
What is the FDA regulatory status of hydrochlorothiazide and methyldopa?
Both ingredients are established FDA-regulated prescription drugs. Their regulatory risk is operational rather than exclusivity-driven.
Hydrochlorothiazide
Hydrochlorothiazide is approved for hypertension and edema-related indications. It is available as a single ingredient and in numerous fixed-dose combinations. The FDA has required labeling that addresses electrolyte abnormalities, renal effects, hypersensitivity reactions, and skin-cancer risk associated with cumulative hydrochlorothiazide exposure in certain populations (FDA, 2020).
Methyldopa
Methyldopa is approved for hypertension. Its labeling includes warnings concerning hepatic injury, hemolytic anemia, sedation, and withdrawal-related blood-pressure increases (FDA, 2023). These safety considerations reduce its attractiveness for routine chronic hypertension treatment.
Combination-product implications
A fixed-dose combination can reduce pill burden but also creates dosing rigidity. Methyldopa and hydrochlorothiazide may require different titration strategies, which limits the clinical value of combining them in a single tablet. A prescriber can adjust each component independently when the ingredients are prescribed separately.
What are the main market dynamics affecting sales?
The market is driven by price and availability rather than product differentiation.
1. Generic price compression
Multiple suppliers and limited clinical differentiation place downward pressure on reimbursement and net pricing. The combination lacks the brand premium associated with newer antihypertensive products.
2. Therapeutic substitution
Prescribers can substitute separate tablets or use better-established fixed-dose combinations. Hydrochlorothiazide is frequently paired with an ACE inhibitor or ARB, while methyldopa is often replaced by labetalol or nifedipine when pregnancy-related hypertension is being treated.
3. Clinical guideline pressure
Current hypertension guidelines generally prioritize thiazide-type diuretics, ACE inhibitors, ARBs, and calcium-channel blockers. Methyldopa is not a preferred broad-market therapy because of adverse-effect and monitoring concerns (Whelton et al., 2018).
4. Procurement concentration
Although the ingredients are inexpensive, a small number of manufacturers may supply a large share of a particular strength or presentation at a given time. This can produce intermittent availability issues without creating durable pricing power.
5. Low switching costs
Substitution between generic suppliers is straightforward when strengths, dosage forms, and labeling are equivalent. Pharmacies and purchasing organizations can shift volume based on price, supply reliability, and wholesaler terms.
What is the financial trajectory of hydrochlorothiazide/methyldopa?
The financial trajectory is mature to declining, with no identifiable mechanism for substantial revenue expansion absent a new formulation, new indication, or supply disruption.
| Period | Financial direction | Principal explanation |
|---|---|---|
| Historical branded period | Growth followed by maturity | Adoption of Aldoril for hypertension |
| Early generic period | Sharp decline in unit price | Entry of multiple generic manufacturers |
| Mature generic period | Stable low-value demand | Persistent use of hydrochlorothiazide and limited methyldopa use |
| Current market | Flat to declining combination revenue | Therapeutic substitution and limited brand presence |
| Long-term outlook | Low, fragmented revenue | No exclusivity, weak differentiation, and declining use of methyldopa |
Public company filings generally do not report hydrochlorothiazide/methyldopa revenue as a separate line item. Sales are usually aggregated within broader generic portfolios. As a result, the combination's financial value is better measured through prescription volume, channel availability, reimbursement rates, and supplier participation than through reported product revenue.
Hydrochlorothiazide remains financially relevant at the ingredient and combination-portfolio level. Methyldopa contributes less value because demand is narrower and generic pricing is low. The combined product does not capture the full commercial value of hydrochlorothiazide because the methyldopa component limits the addressable market.
How strong is the patent estate for hydrochlorothiazide/methyldopa?
The patent estate is weak.
| Patent-strength factor | Assessment |
|---|---|
| Active composition patent | None of commercial significance |
| Active combination patent | None of commercial significance |
| Formulation differentiation | Limited |
| Manufacturing barrier | Limited and supplier-specific |
| Regulatory exclusivity | None |
| Litigation leverage | Low |
| Generic entry risk | Already realized |
| Licensing value | Low |
| Opportunity for life-cycle management | Dependent on a new formulation or new clinical use |
A company seeking to commercialize the combination would rely on manufacturing efficiency, distribution, procurement contracts, or a differentiated dosage form rather than patent exclusivity. Licensing an old combination would have limited value unless the license included a strong supply position, a regional market authorization, or a proprietary formulation.
What licensing deals and settlement agreements affect the market?
No major current licensing deal or patent settlement is associated with the legacy hydrochlorothiazide/methyldopa combination. The absence of active patent disputes means there is no comparable settlement framework to those found in high-revenue branded pharmaceuticals.
Any commercial agreement would more likely involve:
- Contract manufacturing.
- Regional distribution.
- Supply guarantees.
- Private-label generic distribution.
- Hospital or government procurement.
- Product transfers after manufacturer discontinuation.
These arrangements can influence short-term availability but do not create durable exclusivity.
What generic launch scenarios exist?
The likely market scenarios are operational rather than litigation-driven.
Base case
Generic availability continues through a limited group of suppliers. Pricing remains low, and demand gradually shifts toward separate agents or alternative pregnancy-hypertension therapies.
Downside case
Manufacturers discontinue low-volume strengths or the combination entirely. Pharmacies substitute separate methyldopa and hydrochlorothiazide tablets or use other antihypertensive regimens.
Upside case
A manufacturer introduces a reliable low-cost product with improved supply continuity or a differentiated formulation. Volume may improve, but pricing power would remain limited because the underlying ingredients are generic.
Disruption case
A temporary shortage at one or more suppliers creates short-term price increases or procurement opportunities. Such increases would be vulnerable to new supplier entry and therapeutic substitution.
What geographic markets offer the strongest opportunity?
The strongest remaining opportunity is in markets where:
- Methyldopa continues to be used in pregnancy-related hypertension.
- Fixed-dose combinations are preferred for adherence.
- Generic competition is less intense.
- Local regulatory approval is already available.
- Distribution channels favor established suppliers.
The United States is a low-attractiveness market for a branded relaunch because generic substitution is strong and methyldopa has a narrow role. Certain emerging markets may have more persistent demand, but pricing, tender dependence, local manufacturing requirements, and regulatory execution would determine profitability. Geographic expansion would be a volume strategy, not an exclusivity strategy.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are modest but not zero. Suppliers must manage:
- Consistent assay and content uniformity.
- Stability of the combination tablet.
- Impurity control.
- Dissolution and bioequivalence requirements.
- Methyldopa-related degradation concerns.
- Hydrochlorothiazide content uniformity at low doses.
- Reliable sourcing of both active ingredients.
The principal commercial risk is not patent infringement. It is whether expected volume supports validated production, regulatory maintenance, pharmacovigilance, and distribution costs.
Key Takeaways
- Hydrochlorothiazide/methyldopa is a mature generic combination with limited current commercial relevance.
- Aldoril's historical brand value and exclusivity have expired.
- No material active patent estate, Paragraph IV campaign, or settlement framework supports current pricing power.
- Hydrochlorothiazide remains a high-volume generic ingredient, but methyldopa has a narrower and more specialized market.
- Labetalol, nifedipine, ACE inhibitor combinations, ARB combinations, and calcium-channel blocker regimens compete directly or indirectly with the product.
- Current revenue is low, fragmented, and generally not reported separately by manufacturers.
- The main risks are therapeutic substitution, product discontinuation, low pricing, and supply volatility.
- Commercial upside would require a new formulation, improved supply position, or targeted geographic strategy rather than reliance on legacy patents.
FAQs
Is hydrochlorothiazide/methyldopa still sold in the United States?
The ingredients remain available as generic prescription medicines, but the historical fixed-dose combination has limited current visibility and availability compared with separate hydrochlorothiazide and methyldopa products.
Is Aldoril still a protected brand?
No. Aldoril is an old antihypertensive brand whose meaningful patent and regulatory exclusivity periods have expired.
Does methyldopa have stronger demand during pregnancy?
Yes. Methyldopa retains a role in pregnancy-related hypertension, although labetalol and extended-release nifedipine are widely used alternatives and may be preferred depending on clinical circumstances.
Can a generic manufacturer obtain new patents on this combination?
A manufacturer could seek patents on a genuinely novel formulation, manufacturing process, dosing regimen, or patient-specific use. A patent on the old active-ingredient combination alone would not provide new protection.
Is hydrochlorothiazide more commercially valuable than methyldopa?
Yes. Hydrochlorothiazide has substantially broader use because it is prescribed alone and in numerous fixed-dose combinations. Methyldopa has lower volume and more limited therapeutic positioning.
References
American College of Obstetricians and Gynecologists. (2019). Chronic hypertension in pregnancy: ACOG practice bulletin, number 203. Obstetrics & Gynecology, 133(1), e26-e50.
U.S. Food and Drug Administration. (2020). Hydrochlorothiazide drug labeling and safety information. https://www.fda.gov/
U.S. Food and Drug Administration. (2023). Methyldopa prescribing information. https://www.accessdata.fda.gov/
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., Williamson, J. D., & Wright, J. T. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115.
More… ↓
